» Articles » PMID: 17467966

Microbiologic Follow-up Study in Adult Bronchiectasis

Overview
Journal Respir Med
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2007 May 1
PMID 17467966
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

There is minimal published longitudinal data about pathogenic microorganisms in adults with bronchiectasis. Therefore a study was undertaken to assess the microbiologic profile over time in bronchiectasis. A prospective study of clinical and microbiologic outcomes was performed. Subjects were assessed by a respiratory physician and sputum sample were collected for analysis. Subjects were followed up and had repeat assessment performed. Eighty-nine subjects were followed up for a period of 5.7+/-3.6 years. On initial assessment the two most common pathogens isolated were Haemophilus influenzae (47%) and Pseudomonas aeruginosa (12%) whilst 21% had no pathogens isolated. On follow-up review results were similar (40% H. influenzae, 18% P. aeruginosa and 26% no pathogens). The prevalence of antibiotic resistance of isolates increased from 13% to 30%. Analysis of a series of H. influenzae isolates showed they were nearly all nontypeable and all were different subtypes. Subjects with no pathogens isolated from their sputum had the mildest disease, while subjects with P. aeruginosa had the most severe bronchiectasis. Many subjects with bronchiectasis are colonized with the same bacterium over an average follow-up of 5 years. Different pathogens are associated with different patterns of clinical disease.

Citing Articles

Clinical Impacts of Isolation in Patients with Bronchiectasis: Findings from KMBARC Registry.

Song J, Sin S, Kang H, Oh Y, Jeong I J Clin Med. 2024; 13(17).

PMID: 39274224 PMC: 11396479. DOI: 10.3390/jcm13175011.


Lung microbiome: new insights into bronchiectasis' outcome.

Azoicai A, Lupu A, Alexoae M, Starcea I, Mocanu A, Lupu V Front Cell Infect Microbiol. 2024; 14:1405399.

PMID: 38895737 PMC: 11183332. DOI: 10.3389/fcimb.2024.1405399.


Clinical outcomes of long-term inhaled combination therapies in patients with bronchiectasis and airflow obstruction.

Lee H, Lee J, Park T, Heo E, Kim D, Lee H BMC Pulm Med. 2024; 24(1):49.

PMID: 38263115 PMC: 10804611. DOI: 10.1186/s12890-024-02867-4.


Microbiology sampling in non-cystic fibrosis bronchiectasis cases from northern Alberta.

Wagner M, Dimitrov M, Lam G, Leung W, Tyrrell G, Vethanayagam D PLoS One. 2023; 18(7):e0288704.

PMID: 37450508 PMC: 10348526. DOI: 10.1371/journal.pone.0288704.


Coexistence of COVID-19, Pseudomonas, and thoracic actinomycosis in a cystic bronchiectasis case.

Afsin E, Kucuk F, Ozcelik H, Haktanir M BMC Infect Dis. 2023; 23(1):203.

PMID: 37024776 PMC: 10078035. DOI: 10.1186/s12879-023-08215-x.